Skip to main content

Articles

Page 16 of 33

  1. Electrophysiological studies show that reductions in power within the alpha band are associated with the Alzheimer’s disease (AD) continuum. Physical activity (PA) is a protective factor that has proved to red...

    Authors: Jaisalmer de Frutos-Lucas, Pablo Cuesta, Federico Ramírez-Toraño, Alberto Nebreda, Esther Cuadrado-Soto, África Peral-Suárez, David Lopez-Sanz, Ricardo Bruña, Silvia Marcos-de Pedro, María Luisa Delgado-Losada, Ana María López-Sobaler, Inmaculada Concepción Rodríguez-Rojo, Ana Barabash, Juan Manuel Serrano Rodriguez, Simon M. Laws, Alberto Marcos Dolado…
    Citation: Alzheimer's Research & Therapy 2020 12:113
  2. There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant famili...

    Authors: Philip S. J. Weston, Teresa Poole, Jennifer M. Nicholas, Nicolas Toussaint, Ivor J. A. Simpson, Marc Modat, Natalie S. Ryan, Yuying Liang, Martin N. Rossor, Jonathan M. Schott, Sebastien Ourselin, Hui Zhang and Nick C. Fox
    Citation: Alzheimer's Research & Therapy 2020 12:112
  3. Neurofilament light chain (NfL) is a promising biomarker of neurodegeneration in the cerebrospinal fluid and blood. This study investigated the presence of NfL in the vitreous humor and its associations with a...

    Authors: Manju L. Subramanian, Viha Vig, Jaeyoon Chung, Marissa G. Fiorello, Weiming Xia, Henrik Zetterberg, Kaj Blennow, Madeleine Zetterberg, Farah Shareef, Nicole H. Siegel, Steven Ness, Gyungah R. Jun and Thor D. Stein
    Citation: Alzheimer's Research & Therapy 2020 12:111
  4. Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.

    Authors: Tao Wang, Weihong Kuang, Wei Chen, Wenwei Xu, Liming Zhang, Yingjie Li, Hailin Li, Ying Peng, Yangmei Chen, Baojun Wang, Jinsong Xiao, Honghua Li, Chuanzhu Yan, Yifeng Du, Mouni Tang, Zhiyi He…
    Citation: Alzheimer's Research & Therapy 2020 12:110
  5. Alzheimer’s disease (AD) mutations in amyloid precursor protein (APP) and presenilins (PSENs) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ1–43 is more prone to a...

    Authors: Federica Perrone, Maria Bjerke, Elisabeth Hens, Anne Sieben, Maarten Timmers, Arne De Roeck, Rik Vandenberghe, Kristel Sleegers, Jean-Jacques Martin, Peter P. De Deyn, Sebastiaan Engelborghs, Julie van der Zee, Christine Van Broeckhoven and Rita Cacace
    Citation: Alzheimer's Research & Therapy 2020 12:108
  6. To clarify whether atherosclerosis of the carotid and intracranial arteries is related to Alzheimer’s disease (AD) pathology in vivo, we investigated the associations of carotid and intracranial artery stenosi...

    Authors: Koung Mi Kang, Min Soo Byun, Jun Ho Lee, Dahyun Yi, Hye Jeong Choi, Eunjung Lee, Younghwa Lee, Jun-Young Lee, Yu Kyeong Kim, Bo Kyung Sohn, Chul-Ho Sohn and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2020 12:106
  7. Early Alzheimer’s disease (AD) diagnosis is vital for development of disease-modifying therapies. Prior to significant brain tissue atrophy, several microstructural changes take place as a result of Alzheimer’...

    Authors: Alfie R. Wearn, Volkan Nurdal, Esther Saunders-Jennings, Michael J. Knight, Hanna K. Isotalus, Serena Dillon, Demitra Tsivos, Risto A. Kauppinen and Elizabeth J. Coulthard
    Citation: Alzheimer's Research & Therapy 2020 12:105
  8. To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzhei...

    Authors: Clara Vila-Castelar, Nathalia Muñoz, Kathryn V. Papp, Rebecca E. Amariglio, Ana Baena, Edmarie Guzmán-Vélez, Yamile Bocanegra, Justin S. Sanchez, Eric M. Reiman, Keith A. Johnson, Reisa A. Sperling, Francisco Lopera, Dorene M. Rentz and Yakeel T. Quiroz
    Citation: Alzheimer's Research & Therapy 2020 12:104
  9. Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-...

    Authors: Daniel Lancour, Josée Dupuis, Richard Mayeux, Jonathan L. Haines, Margaret A. Pericak-Vance, Gerard C. Schellenberg, Mark Crovella, Lindsay A. Farrer and Simon Kasif
    Citation: Alzheimer's Research & Therapy 2020 12:103
  10. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of middle-aged to old individuals. The pathophysiological process of AD is believed to begin many years before the emergence of clinical sym...

    Authors: Wei Wei, Yifan Wang, Yinghua Liu, Chun-Ling Dai, Yunn-Chyn Tung, Fei Liu and Khalid Iqbal
    Citation: Alzheimer's Research & Therapy 2020 12:102
  11. Recent evidence indicates that disrupted sleep could contribute to the development of Alzheimer’s disease by influencing the production and/or clearance of the amyloid-β protein. We set up a case-control study...

    Authors: Jana Thomas, Sharon J. Ooms, Lara J. Mentink, Jan Booij, Marcel G. M. Olde Rikkert, Sebastiaan Overeem, Roy P. C. Kessels and Jurgen A. H. R. Claassen
    Citation: Alzheimer's Research & Therapy 2020 12:101
  12. Intensive basic and preclinical research into Alzheimer’s disease (AD) has yielded important new findings, but they could not yet been translated into effective therapies. One of the reasons is the lack of ani...

    Authors: Amira Latif-Hernandez, Victor Sabanov, Tariq Ahmed, Katleen Craessaerts, Takashi Saito, Takaomi Saido and Detlef Balschun
    Citation: Alzheimer's Research & Therapy 2020 12:100
  13. Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer’s disease (AD), especially when they require the binding o...

    Authors: Daniel J. Norton, Mario A. Parra, Reisa A. Sperling, Ana Baena, Edmarie Guzman-Velez, David S. Jin, Nicholas Andrea, Juna Khang, Aaron Schultz, Dorene M. Rentz, Enmanuelle Pardilla-Delgado, Joshua Fuller, Keith Johnson, Eric M. Reiman, Francisco Lopera and Yakeel T. Quiroz
    Citation: Alzheimer's Research & Therapy 2020 12:99
  14. Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the phar...

    Authors: Justin Bauzon, Garam Lee and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2020 12:98

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:139

  15. Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predic...

    Authors: Tengfei Guo, Deniz Korman, Renaud La Joie, Leslie M. Shaw, John Q. Trojanowski, William J. Jagust and Susan M. Landau
    Citation: Alzheimer's Research & Therapy 2020 12:97
  16. The amyloid precursor protein (APP) is a transmembrane glycoprotein that undergoes alternative proteolytic processing. Its processing through the amyloidogenic pathway originates a large sAPPβ ectodomain fragm...

    Authors: Claudia P. Boix, Inmaculada Lopez-Font, Inmaculada Cuchillo-Ibañez and Javier Sáez-Valero
    Citation: Alzheimer's Research & Therapy 2020 12:96
  17. The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful effic...

    Authors: Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson and Marwan Sabbagh
    Citation: Alzheimer's Research & Therapy 2020 12:95
  18. Preventing dementia onset is one of the global public health priorities: around 35% of dementia cases could be attributable to modifiable risk factors. These estimates relied on secondary data and did not cons...

    Authors: Elena Rolandi, Daniele Zaccaria, Roberta Vaccaro, Simona Abbondanza, Laura Pettinato, Annalisa Davin and Antonio Guaita
    Citation: Alzheimer's Research & Therapy 2020 12:94
  19. A substantial number of patients clinically diagnosed with Alzheimer’s disease do not harbor amyloid pathology. We analyzed the presence and extent of tau deposition and neurodegeneration in amyloid-positive (...

    Authors: Eddie C. Stage Jr, Diana Svaldi, Meredith Phillips, Victor Hugo Canela, Tugce Duran, Naira Goukasian, Shannon L. Risacher, Andrew J. Saykin and Liana G. Apostolova
    Citation: Alzheimer's Research & Therapy 2020 12:93
  20. Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer’s disease (AD). The objective of this study was to examine the association of sele...

    Authors: Unnur D. Teitsdottir, Maria K. Jonsdottir, Sigrun H. Lund, Taher Darreh-Shori, Jon Snaedal and Petur H. Petersen
    Citation: Alzheimer's Research & Therapy 2020 12:92
  21. Optimization of vascular risk factor control is emerging as an alternative approach to improve cognitive outcomes in Alzheimer’s disease, although its efficacy is still under debate. We aimed to investigate th...

    Authors: Yu-Wen Cheng, Ming-Jang Chiu, Ya-Fang Chen, Ting-Wen Cheng, Ya-Mei Lai and Ta-Fu Chen
    Citation: Alzheimer's Research & Therapy 2020 12:91
  22. The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and...

    Authors: Dana B. DiBenedetti, Christina Slota, Samantha L. Wronski, George Vradenburg, Meryl Comer, Leigh F. Callahan, John Winfield, Ivana Rubino, Holly B. Krasa, Ann Hartry, Dan Wieberg, Ian N. Kremer, Debra Lappin, Allison D. Martin, Terry Frangiosa, Virginia Biggar…
    Citation: Alzheimer's Research & Therapy 2020 12:90
  23. Neurogenesis is significantly impaired in the brains of both human patients and experimental animal models of Alzheimer’s disease (AD). Although deep brain stimulation promotes neurogenesis, it is an invasive ...

    Authors: Qian Liu, Yihang Jiao, Weijian Yang, Beiyao Gao, Daniel K. Hsu, Jan Nolta, Michael Russell, Bruce Lyeth, Theodore P. Zanto and Min Zhao
    Citation: Alzheimer's Research & Therapy 2020 12:89
  24. The presynaptic protein neuregulin1 (NRG1) is cleaved by beta-site APP cleaving enzyme 1 (BACE1) in a similar way as amyloid precursor protein (APP) NRG1 can activate post-synaptic receptor tyrosine-protein ki...

    Authors: François Mouton-Liger, Julien Dumurgier, Emmanuel Cognat, Claire Hourregue, Henrik Zetterberg, Hugo Vanderstichele, Eugeen Vanmechelen, Elodie Bouaziz-Amar, Kaj Blennow, Jacques Hugon and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2020 12:88
  25. With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimer’s disease (AD) is the most common cause of dementia, and no curative treatment is availabl...

    Authors: Daichi Shigemizu, Taiki Mori, Shintaro Akiyama, Sayuri Higaki, Hiroshi Watanabe, Takashi Sakurai, Shumpei Niida and Kouichi Ozaki
    Citation: Alzheimer's Research & Therapy 2020 12:87
  26. The neuroprotective role of interleukin (IL)-33 is supported by numerous preclinical studies, but it remains uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association ...

    Authors: Chih-Sung Liang, Kuan-Pin Su, Chia-Lin Tsai, Jiunn-Tay Lee, Che-Sheng Chu, Ta-Chuan Yeh, Ming-Wei Su, Guan-Yu Lin, Yu-Kai Lin, Hsuan-Te Chu, Chia-Kuang Tsai and Fu-Chi Yang
    Citation: Alzheimer's Research & Therapy 2020 12:86
  27. Cognitive impairment is an important consequence of stroke and transient ischaemic attack, but its determinants are not fully understood. Simple univariable or multivariable models have not shown clinical util...

    Authors: Bogna A. Drozdowska, Emma Elliott, Martin Taylor-Rowan, Robert C. Shaw, Gillian Cuthbertson, Peter Langhorne and Terence J. Quinn
    Citation: Alzheimer's Research & Therapy 2020 12:85
  28. Disturbed sleep is associated with cognitive decline in neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The progressive sequence of how neurodegeneration affects ...

    Authors: C. M. Holton, N. Hanley, E. Shanks, P. Oxley, A. McCarthy, B. J. Eastwood, T. K. Murray, A. Nickerson and K. A. Wafford
    Citation: Alzheimer's Research & Therapy 2020 12:84
  29. Recently, several studies suggested potential involvements of α-synuclein in Alzheimer’s disease (AD) pathophysiology. Higher concentrations of α-synuclein were reported in cerebrospinal fluid (CSF) of AD pati...

    Authors: Kyu Hwan Shim, Min Ju Kang, Jee Won Suh, Jung-Min Pyun, Nayoung Ryoo, Young Ho Park, Young Chul Youn, Jae-Won Jang, Jee Hyang Jeong, Kyung Won Park, Seong Hye Choi, Kyoungho Suk, Ho-Won Lee, Pan-Woo Ko, Chan-Nyoung Lee, Tae-Sung Lim…
    Citation: Alzheimer's Research & Therapy 2020 12:83
  30. To investigate using quantitative EEG the (1) differences between patients with mild cognitive impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer’s disease (MCI-AD) and (2) its utility as a potential ...

    Authors: Julia Schumacher, John-Paul Taylor, Calum A. Hamilton, Michael Firbank, Ruth A. Cromarty, Paul C. Donaghy, Gemma Roberts, Louise Allan, Jim Lloyd, Rory Durcan, Nicola Barnett, John T. O’Brien and Alan J. Thomas
    Citation: Alzheimer's Research & Therapy 2020 12:82
  31. Recently, it has been suggested that up to a third of the dementia cases might be preventable. While prevention is always better than cure, this is particularly important in the field of dementia, as current i...

    Authors: Manuel Montero-Odasso, Zahinoor Ismail and Gill Livingston
    Citation: Alzheimer's Research & Therapy 2020 12:81
  32. Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid β-protein (Aβ) and the microtubule-associated protein, tau, and has been genetically linked to late-onset Alzheimer disease (AD). Here,...

    Authors: Caitlin N. Suire, Samer O. Abdul-Hay, Tomoko Sahara, Dongcheul Kang, Monica K. Brizuela, Paul Saftig, Dennis W. Dickson, Terrone L. Rosenberry and Malcolm A. Leissring
    Citation: Alzheimer's Research & Therapy 2020 12:80
  33. Despite the growing number of discoveries during the past decades about its functions, the insula remains a mysterious ‘island’. In addition to its involvement in basic functions such as gustation and interoce...

    Authors: Nathalie Philippi, Vincent Noblet, Malik Hamdaoui, David Soulier, Anne Botzung, Emmanuelle Ehrhard, Benjamin Cretin and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2020 12:79
  34. Growing awareness of Alzheimer’s disease (AD) has prompted a demand for quick and effective ways to screen for memory loss and cognitive decline in large numbers of individuals in the community. Periodic Memor...

    Authors: Guerry M. Peavy, Cecily W. Jenkins, Emily A. Little, Christina Gigliotti, Amanda Calcetas, Steven D. Edland, James B. Brewer, Douglas Galasko and David P. Salmon
    Citation: Alzheimer's Research & Therapy 2020 12:78
  35. Current demographic trends point towards an aging society entailing increasing occurrence and burden of neurodegenerative diseases. In this context, understanding physiological aging and its turning point into...

    Authors: Alexa Haeger, Jean-François Mangin, Alexandre Vignaud, Cyril Poupon, Antoine Grigis, Fawzi Boumezbeur, Vincent Frouin, Jean-Robert Deverre, Marie Sarazin, Lucie Hertz-Pannier and Michel Bottlaender
    Citation: Alzheimer's Research & Therapy 2020 12:77
  36. Sedentary behaviour might be a potential risk factor for cognitive decline. However, the short-term effects of sedentary behaviour on (cerebro) vascular and cognitive performance in older people are unknown.

    Authors: Carlijn M. Maasakkers, René J. F. Melis, Roy P. C. Kessels, Paul A. Gardiner, Marcel G. M. Olde Rikkert, Dick H. J. Thijssen and Jurgen A. H. R. Claassen
    Citation: Alzheimer's Research & Therapy 2020 12:76
  37. All cells accumulate insoluble protein aggregates throughout their lifespan. While many studies have characterized the canonical disease-associated protein aggregates, such as those associated with amyloid pla...

    Authors: Devin Kepchia, Ling Huang, Richard Dargusch, Robert A. Rissman, Maxim N. Shokhirev, Wolfgang Fischer and David Schubert
    Citation: Alzheimer's Research & Therapy 2020 12:75
  38. Quantifying changes in the levels of biological and cognitive markers prior to the clinical presentation of Alzheimer’s disease (AD) will provide a template for understanding the underlying aetiology of the cl...

    Authors: Christoforos Hadjichrysanthou, Stephanie Evans, Sumali Bajaj, Loizos C. Siakallis, Kevin McRae-McKee, Frank de Wolf and Roy M. Anderson
    Citation: Alzheimer's Research & Therapy 2020 12:74
  39. The retina and the brain share anatomic, embryologic, and physiologic characteristics. Therefore, retinal imaging in patients with brain disorders has been of significant interest. Using optical coherence tomo...

    Authors: Ju-Yeun Lee, Jun Pyo Kim, Hyemin Jang, Jaeho Kim, Sung Hoon Kang, Ji Sun Kim, Jongmin Lee, Young Hee Jung, Duk L. Na, Sang Won Seo, Sei Yeul Oh and Hee Jin Kim
    Citation: Alzheimer's Research & Therapy 2020 12:73
  40. Heme and iron homeostasis is perturbed in Alzheimer’s disease (AD); therefore, the aim of the study was to examine the levels and association of heme with iron-binding plasma proteins in cognitively normal (CN...

    Authors: Azhaar Ashraf, Nicholas J. Ashton, Pratishtha Chatterjee, Kathryn Goozee, Kaikai Shen, Jurgen Fripp, David Ames, Christopher Rowe, Colin L. Masters, Victor Villemagne, Abdul Hye, Ralph N. Martins and Po-Wah So
    Citation: Alzheimer's Research & Therapy 2020 12:72
  41. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…
    Citation: Alzheimer's Research & Therapy 2020 12:71

    The original article was published in Alzheimer's Research & Therapy 2020 12:56

  42. Recent studies indicated that circulatory factors in blood plasma from young animals can reactivate neurogenesis, restore synaptic plasticity, and improve cognitive function in aged animals. Here, we investiga...

    Authors: Ying Zhao, Ran Qian, Jin Zhang, Fei Liu, Khalid Iqbal, Chun-Ling Dai and Cheng-Xin Gong
    Citation: Alzheimer's Research & Therapy 2020 12:70
  43. Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, les...

    Authors: Michael T. Heneka, Douglas Golenbock, Eicke Latz, Dave Morgan and Robert Brown
    Citation: Alzheimer's Research & Therapy 2020 12:69
  44. Although numerous electroencephalogram (EEG) studies have described differences in functional connectivity in Alzheimer’s disease (AD) compared to healthy subjects, there is no general consensus on the methodo...

    Authors: Casper T. Briels, Deborah N. Schoonhoven, Cornelis J. Stam, Hanneke de Waal, Philip Scheltens and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2020 12:68
  45. There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer’s disease (AD) treatment trials. We reported previously a composite cognitive...

    Authors: Jessica B. Langbaum, Noel N. Ellison, Angelika Caputo, Ronald G. Thomas, Carolyn Langlois, Marie-Emmanuelle Riviere, Ana Graf, Cristina Lopez Lopez, Eric M. Reiman, Pierre N. Tariot and Suzanne B. Hendrix
    Citation: Alzheimer's Research & Therapy 2020 12:66
  46. Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprote...

    Authors: Elles Konijnenberg, Betty M. Tijms, Johan Gobom, Valerija Dobricic, Isabelle Bos, Stephanie Vos, Magda Tsolaki, Frans Verhey, Julius Popp, Pablo Martinez-Lage, Rik Vandenberghe, Alberto Lleó, Lutz Frölich, Simon Lovestone, Johannes Streffer, Lars Bertram…
    Citation: Alzheimer's Research & Therapy 2020 12:65
  47. Our objectives were to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on tri...

    Authors: Ningyuan Zhang, Xijun Zheng, Hongxia Liu, Qingshan Zheng and Lujin Li
    Citation: Alzheimer's Research & Therapy 2020 12:64
  48. Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative diseases. Cerebral deposition of Aβ peptides, especially Aβ42, is considered the major neuropathological hallmark of AD and the...

    Authors: Tugce Munise Satir, Lotta Agholme, Anna Karlsson, Mattias Karlsson, Paul Karila, Sebastian Illes, Petra Bergström and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2020 12:63